Compare CYTK & BEPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYTK | BEPC |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.4B |
| IPO Year | 2004 | N/A |
| Metric | CYTK | BEPC |
|---|---|---|
| Price | $68.45 | $41.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $77.87 | $39.75 |
| AVG Volume (30 Days) | ★ 1.9M | 1.4M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 3.60% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $87,211,000.00 | ★ $3,828,000,000.00 |
| Revenue This Year | $363.61 | $43.05 |
| Revenue Next Year | $64.33 | $9.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2609.26 | N/A |
| 52 Week Low | $29.31 | $23.73 |
| 52 Week High | $69.33 | $45.10 |
| Indicator | CYTK | BEPC |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 50.01 |
| Support Level | $59.85 | $40.17 |
| Resistance Level | $67.98 | $41.96 |
| Average True Range (ATR) | 2.72 | 1.17 |
| MACD | 0.13 | -0.38 |
| Stochastic Oscillator | 91.35 | 25.15 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia, and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners LP and Brookfield Renewable Corp.